|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||64.31 - 64.75|
|52 Week Range||64.31 - 64.75|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||2.08 (3.22%)|
|1y Target Est||N/A|
How Gilead Sciences wooed Warren Buffett and other things you probably didn't know about the big biotech.
Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20%.
Gilead Sciences’ (GILD) tenofovir alafenamide fumarate (or TAF) based regimens have seen high adoption rates in the US and European markets.